Results 191 to 200 of about 59,781 (255)

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Cancer pain: current practice and emerging targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye   +5 more
wiley   +1 more source

Peripheral targets for neuropathic pain

open access: yesBritish Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour   +3 more
wiley   +1 more source

GLP‐1 receptor activation attenuates chronic migraine‐like behaviour: Sex‐specific modulation of opioid‐ and endocannabinoid‐related pathways

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Chronic migraine (CM) is a highly disabling condition that remains suboptimally treated. Metabolic disturbances may trigger migraine chronification, whereas impaired endogenous pain inhibition contributes to CM development. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), used for type 2 diabetes and obesity, show efficacy ...
Katarina Sićović   +6 more
wiley   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

Identification of Copy Number Variants as a Suspected Cause of Cerebral Small Vessel Disease

open access: yesClinical Genetics, EarlyView.
Whole‐exome sequencing of 111 patients with suspected familial cerebral small vessel disease (CSVD) identified novel copy number variants in four patients across NOTCH3, LMNB1, and COL4A2, using bioinformatic and molecular techniques. These validated CNVs suggest structural variation is an underrecognized potential causal contributor to monogenic CSVD ...
Solomon K. Guyler   +5 more
wiley   +1 more source

Depressive and Anxiety Symptoms in Vestibular Migraine and Probable Vestibular Migraine

open access: yesClinical Otolaryngology, EarlyView.
ABSTRACT Introduction It has been previously reported that patients with vestibular migraine (VM) are more prone to anxiety and depressive symptoms. However, the association between the pathophysiology of VM and anxiety and depressive symptoms is still unclear.
Chisato Fujimoto   +6 more
wiley   +1 more source

Vertigo and dizziness syndromes in children and adolescents: Clinical presentation and diagnostic pathway

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
This study characterized 519 children and adolescents with vertigo using clinical, diagnostic, imaging, quality‐of‐life, and demographic data, identifying vestibular migraine as the most frequent diagnosis, followed by functional dizziness and recurrent vertigo of childhood.
Doreen Huppert   +7 more
wiley   +1 more source

Neuropsychiatric Outcomes Associated With GLP‐1 Receptor Agonist Use in Medicare Beneficiaries With Type 2 Diabetes: Variation by Treatment Pattern and Obesity Status

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Glucagon‐like peptide‐1 (GLP‐1) receptors are expressed in brain regions governing mood, reward and stress, yet the neuropsychiatric effects of GLP‐1 receptor agonist (GLP‐1 RA) therapy remain poorly characterized. We estimated associations between GLP‐1 RA use and neuropsychiatric disorders and variation by obesity status and treatment ...
Seo Hyon Baik   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy